文献速递临床试验与 GCP

西罗莫司涂层球囊血管成形术对比普通球囊血管成形术治疗透析通路功能障碍(IMPRESSION):随机对照试验研究方案

SIroliMus coated angioPlasty versus plain balloon angioplasty in the tREatment of dialySis acceSs dysfunctION (IMPRESSION): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-12-20

本研究为研究者发起的前瞻性多中心双盲随机对照试验,计划纳入170例因动静脉内瘘功能障碍需行球囊血管成形术的成熟动静脉内瘘患者,按1:1随机分配至西罗莫司涂层球囊组或普通球囊组,按动静脉内瘘位置分层,随访至1年,主要终点为6个月时通路电路一期通畅率。

要点

  • 西罗莫司涂层球囊在冠状动脉中已证明可改善通畅率,但对动静脉通路的效果尚未研究。
  • 计划纳入170例21至85岁需球囊血管成形术的成熟动静脉内瘘功能障碍患者,1:1随机分组。
  • 主要终点为6个月时通路电路一期通畅率,随访至1年。

核心结论

  • 本研究将评估西罗莫司涂层球囊对比普通球囊在血液透析患者动静脉内瘘狭窄治疗中的临床疗效与安全性。

研究设计与样本

  • 研究者发起的前瞻性、多中心、双盲、随机对照临床试验,计划纳入170例因动静脉内瘘功能障碍需经皮腔内血管成形术的成熟动静脉内瘘患者,按1:1随机分配至西罗莫司涂层球囊组或普通球囊组,按动静脉内瘘位置分层,随访至1年。

关键数值与推荐

  • 纳入标准包括年龄21至85岁需球囊血管成形术的动静脉内瘘功能障碍成人患者。
  • 成熟动静脉内瘘定义为血管成形术前已使用至少1个月。
  • 普通球囊成功血管成形术定义为数字减影血管造影(DSA)上残余狭窄小于30%且临床检查动静脉内瘘震颤恢复。
  • 排除标准包括治疗时通路电路血栓形成或部分血栓形成、存在需治疗的症状性或血管造影显著的中心静脉狭窄且血管成形术后残余狭窄超过30%、以及动静脉内瘘电路内已有支架置入。
  • 主要终点为6个月时通路电路一期通畅率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Percutaneous transluminal angioplasty is the current standard treatment for arteriovenous fistula (AVF) stenosis. The mid- and long-term patency with plain balloon angioplasty (PBA) is however far from satisfactory. While paclitaxel-coated balloon angioplasty has been shown to be superior to PBA, concern over its safety profile has recently arisen after a reported possible increased mortality risk with a meta-analysis of large lower limb studies. An angioplasty balloon with a new type of drug coating, the sirolimus-coated balloon (SCB), has been proven to improve patency in the coronary arteries. However, its effect on AV access has yet to be studied. METHODS/DESIGN: This is an investigator-initiated, prospective, multicenter, double-blinded, randomized controlled clinical trial to assess the effectiveness of SCB compared to PBA in improving the patency of AVF after angioplasty. A total of 170 patients with mature AVF that requires PTA due to AVF dysfunction will be randomly assigned to treatment with a SCB or PBA at a 1:1 ratio, stratified by location of AVF and followed up for up to 1 year. The inclusion criteria include [1] adult patient aged 21 to 85 years who requires balloon angioplasty for dysfunctional arteriovenous fistula [2]; matured AVF, defined as being in use for at least 1 month prior to the angioplasty; and [3] successful angioplasty of the underlying stenosis with PBA, defined as less than 30% residual stenosis on digital subtraction angiography (DSA) and restoration of thrill in the AVF on clinical examination. The exclusion criteria include thrombosed or partially thrombosed access circuit at the time of treatment, presence of symptomatic or angiographically significant central vein stenosis that requires treatment with more than 30% residual stenosis post angioplasty, and existing stent placement within the AVF circuit. The primary endpoint of the study is access circuit primary patency at 6 months. The secondary endpoints are target lesion primary patency; access circuit-assisted primary patency; access circuit secondary patency at 3, 6, and 12 months; target lesion restenosis rate at 6 months; total number of interventions; complication rate; and cost-effectiveness. The trial is supported by Concept Medical. DISCUSSION: This study will evaluate the clinical efficacy and safety of SCB compared to PBA in the treatment of AVF stenosis in hemodialysis patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT04409912 . Registered on 1 June 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Pang SC, Tan RY, Choke E, et al. SIroliMus coated angioPlasty versus plain balloon angioplasty in the tREatment of dialySis acceSs dysfunctION (IMPRESSION): study protocol for a randomized controlled trial. Trials. 2021. PMID: 34930401. doi:10.1186/s13063-021-05920-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。